Benzinga | Sep 13, 2020 08:32PM EDT

89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH on Monday, September 14, 2020

89bio, Inc. (NASDAQ:ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study of BIO89-100 in NASH in a pre-market press release and webcast to be held on Monday, September 14, 2020.

Conference Call/Webcast DetailsThe company will host a conference call and webcast with slides at 8:30am PT (5:30am PT) tomorrow morning, September 14. Details for the live conference call are as follows: Domestic (833) 570-1145; International (914) 987-7092; and Passcode - 5064866. To access the live webcast and slides, please visit "Events and Presentations" under the "Investors" section of 89bio's website at https://ir.89bio.com/events-and-presentations. Following the live audio webcast, a replay will be available on the company's website for 90 days.